Trilantic North America inks $945m sale of SOFIE Biosciences to GE HealthCare
🇬🇧 English
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
🇸🇦 العربية
تريلانتيك تبيع SOFIE Biosciences إلى GE HealthCare مقابل 945 مليون دولار
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
ما هو التأثير المالي المتوقع لاستحواذ SOFIE Biosciences على GE Health Care؟
تتوقع GE Health Care أن تكون الصفقة مُساهمة في نمو الدخل، والهامش المعدل لـ EBIT، والأرباح المعدلة لكل سهم في السنة الكاملة الأولى من الملكية، مع توقع نمو SOFIE Biosciences بأرقام مزدوجة منخفضة.
🇧🇩 বাংলা
Trilantic ৯৪৫ মিলিয়ন ডলারে SOFIE Biosciences বিক্রি করেছে GE HealthCare-কে
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
SOFIE Biosciences অধিগ্রহণের GE Health Care-কে আশাপ্রত্যাশিত আর্থিক প্রভাব কী?
GE Health Care আশা করে যে এই চুক্তি মালিকানোর প্রথম পূর্ণ বছরে আয় বৃদ্ধি, সমন্বিত EBIT মার্জিন এবং সমন্বিত প্রতি শেয়ার আয়কে বাড়iatবে, এবং SOFIE Biosciences-ниজের অংশ olarak নিম্ন দুহার অঙ্কে বৃদ্ধি পাবে।
🇩🇪 Deutsch
Trilantic verkauft SOFIE Biosciences an GE HealthCare für 945 Millionen Dollar
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
Wie lautet die erwartete finanzielle Auswirkung der Übernahme von SOFIE Biosciences durch GE Health Care?
GE Health Care erwartet, dass der Deal das Umsatzwachstum, die angepasste EBIT-Marge und den angepassten Gewinn pro Aktie im ersten vollständigen Jahr der Eigentümerschaft positiv beeinflussen wird, wobei SOFIE Biosciences ein Wachstum im unteren zweistelligen Bereich erwartet wird.
🇪🇸 Español
Trilantic vende SOFIE Biosciences a GE HealthCare por 945 millones de dólares
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
¿Cuál es el impacto financiero esperado de la adquisición de SOFIE Biosciences en GE Health Care?
GE Health Care espera que el acuerdo sea acrecentador para el crecimiento de los ingresos, el margen ajustado de EBIT y las ganancias ajustadas por acción en el primer año completo de propiedad, con SOFIE Biosciences proyectado para crecer en los dígitos bajos dobles.
🇫🇷 Français
Trilantic vend SOFIE Biosciences à GE HealthCare pour 945 millions de dollars
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
Quel est l'impact financier attendu de l'acquisition de SOFIE Biosciences sur GE Health Care ?
GE Health Care prévoit que l'accord sera relutif pour la croissance des revenus, la marge EBIT ajustée et le bénéfice par action ajusté lors de la première année complète de propriété, avec une croissance prévue de SOFIE Biosciences dans les faibles deux chiffres.
🇮🇳 हिन्दी
Trilantic ने 945 मिलियन डॉलर में SOFIE Biosciences को GE HealthCare को बेचा
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
SOFIE Biosciences के अधिग्रहण का GE Health Care पर अपेक्षित वित्तीय प्रभाव क्या है?
GE Health Care की अपेक्षा है कि यह सौदा स्वामित्व के पहले पूर्ण वर्ष में राजस्व वृद्धि, समायोजित EBIT मार्जिन और समायोजित प्रति शेयर आय में योगदानकारी होगा, साथ ही SOFIE Biosciences का निम्न दोहरे अंकों में वृद्धि होने की उम्मीद है।
🇮🇩 Bahasa Indonesia
Trilantic menjual SOFIE Biosciences kepada GE HealthCare seharga 945 juta dolar
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
Apa dampak keuangan yang diharapkan dari akuisisi SOFIE Biosciences terhadap GE Health Care?
GE Health Care mengharapkan bahwa perkiraan ini akan berkontribusi pada pertumbuhan pendapatan, margin EBIT yang disesuaikan, dan laba per saham yang disesuaikan dalam tahun penuh pertama kepemilikan, dengan pertumbuhan SOFIE Biosciences diproyeksikan dalam angka dua digit rendah.
🇯🇵 日本語
Trilantic、SOFIE BiosciencesをGE HealthCareに9億4500万ドルで売却
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
SOFIE Biosciencesの買収がGE Health Careに与える予想される財務インパクトは何ですか？
GE Health Careは、この取引が所有の最初の完全な年において収益成長、調整後EBITマージン、および調整後1株当たり利益に寄与することを期待しており、SOFIE Biosciencesは低い二桁の成長を見込んでいる。
🇧🇷 Português
Trilantic vende SOFIE Biosciences para a GE HealthCare por US$ 945 milhões
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
Qual é o impacto financeiro esperado da aquisição da SOFIE Biosciences pela GE Health Care?
A GE Health Care espera que o acordo seja accretivo para o crescimento da receita, a margem EBIT ajustada e o lucro por ação ajustado no primeiro ano completo de propriedade, com a SOFIE Biosciences projetada para crescer em dígitos baixos duplos.
🇷🇺 Русский
Trilantic продала SOFIE Biosciences GE HealthCare за 945 миллионов долларов
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
Каково ожидаемое финансовое влияние приобретения SOFIE Biosciences на GE Health Care?
GE Health Care ожидает, что сделка будет способствовать росту выручки, скорректированной марже EBIT и скорректированной прибыли на акцию в первый полный год владения, при этом SOFIE Biosciences, как ожидается, будет расти в нижнем диапазоне двузначных чисел.
🇨🇳 简体中文
Trilantic 以9.45亿美元将SOFIE Biosciences出售给GE HealthCare
Trilantic North America has agreed to sell SOFIE Biosciences to GE Health Care for $945 million in cash. SOFIE Biosciences operates 15 contract manufacturing sites across the US with 21 cyclotrons, along with a theranostics-focused contract development and manufacturing site. The company will continue to operate as an independent manufacturing partner to its customers after the deal closes, including supplying products from other radiopharmaceutical providers.
The acquisition gives GE Health Care US rights to FAPI-74, SOFIE Biosciences’ Phase III F18 fibroblast activation protein inhibitor asset. GE Health Care already holds the rights outside the US. GE Health Care expects SOFIE Biosciences to grow in the low double digits as part of the company.
It also estimates the deal will be accretive to revenue growth, adjusted EBIT margin and adjusted earnings per share in the first full year of ownership. Trilantic North America is a growth-focused middle-market private equity firm that has raised $11.6 billion across seven fund families. The deal is expected to close in the first half of 2027, subject to regulatory approvals, at which point SOFIE Biosciences will become part of GE Health Care’s Pharmaceutical Diagnostics segment.
Bof A Securities, Consello Financial and Solomon Partners Securities served as financial advisers to GE Health Care.
SOFIE Biosciences收购对GE Health Care的预期财务影响是什么？
GE Health Care预计该交易在完全拥有的第一个完整财年将对收入增长、调整后的EBIT利润率和调整后的每股收益产生贡献作用，SOFIE Biosciences预计将以个位数低位增长。